Our Team
Virtual Labs is founder-led today: one scientist-entrepreneur with a conviction that the way we test drugs must change — and open seats for the neuroscientists, computer vision engineers, and drug discovery veterans who will build it with him.
“I feel like every part of my career has been preparing me for this opportunity.”
Background
David trained in neuroscience under Clifford Woolf at Harvard. His PhD dissertation, Analysis of Voluntary Behavior to Interrogate Neural Function, treated behavior as the readout of the nervous system. As first author in Nature Neuroscience (2013), he showed that pain and itch are signaled by distinct nerve fibers. In 2014 he was named a Harvard Horizons Scholar, one of eight chosen from more than 4,000 Harvard PhD students.
He went on to a postdoctoral fellowship in drug development at Harvard Medical School & Boston Children’s Hospital, served as Instructor of Neurology at HMS (2019–2021), and taught neurobiology of behavior and drug addiction courses at Harvard. Beginning in 2013 he worked as an analyst at MIT CSAIL on a DARPA-funded AI project. He also holds an MBA and spent two years in investment banking before moving into science.
Alongside the science, he has founded or co-founded six companies: Blue Therapeutics (co-founder and COO, 2014); Nocion Therapeutics (scientific co-founder and co-inventor, 2017), whose assets are now in Phase 2b clinical trials; Crimson Scientific (co-founder, 2017), which built behavioral equipment for neuroscience labs; AI behavior-screening company, Blackbox Biotech (co-founder and CEO, 2022); Cacti Therapeutics (co-founder, 2022), which is developing nociplastigens for chronic pain; and Virtual Labs. He is a named inventor on six issued U.S. patents spanning automated analysis of rodent behavior and novel approaches to treating pain, itch, cough, and anxiety, with additional patent applications pending. He is an author on 16 peer-reviewed publications in pain neurobiology, sensory neuroscience, immunology, and automated behavioral analysis.
His co-first-author paper in PAIN (2022) laid the groundwork for his discoveries transforming the behavioral neuroscience field. He designs optics, mechanical CAD, and circuit boards himself, and the Virtual Labs technologies he invented are patent-pending. In 2025 he received the Tech Titans Technology Inventor award.
Career & Inventions
Two decades building tools to measure animal behavior.

David invented and built a six-chamber mouse observation enclosure that one video camera could view at once, with near-infrared lighting, mouse-sensing LED timers and filtered air for each chamber. Its stainless finish and angled panels, which resembled the DeLorean in Back to the Future, earned it the nickname. Microphones in every chamber picked up the 10–14 kHz sound of scratching, so itch could be scored automatically. Its data went into his 2013 Nature Neuroscience paper showing that itch and pain are signaled by largely distinct nerve fibers.
Read the paper (Nature Neuroscience, 2013) HMS News: “Selectively Silencing Itch”

His frustrations using commercially available thermal stimulation devices to test whether targeted local anesthetics could silence specific sensory nerves (Roberson, et al., 2011), led David to invent and build a handheld device that applies a precise hot or cold stimulus to a small patch of rodent skin. A Peltier element in an acrylic handle holds any temperature from −10° to 50°C or runs a programmed ramp, and a built-in timer records skin contact.

With Clifford Woolf, David designed and hand-built an enclosure that shields a home cage from laboratory light, sound and odor, with programmable temperature, humidity and lighting. Its resemblance to a keg refrigerator earned it the tongue-in-cheek nickname “the kegerator.” A 3D depth camera in the ceiling recorded voluntary behavior with no observer in the room.

Built with Alex Wiltschko: an open-topped chamber on a Teflon mesh floor over four low-velocity exhaust fans, so odors could be delivered and cleared on cue. The open top let a 3D range camera record olfactory-driven behavior from above, inside the isolation enclosure.

A device for analyzing spontaneous rodent behavior from below, with no observer present. Developed with Alex Wiltschko, S. Robert Datta and Clifford Woolf, it is covered by U.S. Patent 10,238,085, “Devices and methods for analyzing rodent behavior” (filed 2013, issued 2019).

2014 Harvard Horizons Scholar: one of eight out of over four-thousand Harvard PhD students selected to present their research at the annual Harvard Horizons Symposium.

David co-founded Blue Therapeutics in 2014 with Ajay Yekkirala, Michio Painter and Phil Portoghese, at the Harvard Business School Launch Lab, and served as COO. The company developed Blue181, a non-addictive small-molecule painkiller that selectively targets the mu–kappa opioid receptor heterodimer, aiming for opioid-level pain relief with less tolerance and dependence. It was advanced toward IND with non-dilutive NIH/NIDA SBIR and Department of Defense (CDMRP) awards.
Runner-up, 2015 Harvard Deans’ Health and Life Sciences Challenge (Bertarelli Foundation Runner-Up Prize).
In 2015, Blue was a finalist in the MassChallenge and OneStart accelerators and was selected for MassBio’s MassCONNECT mentoring program.


David received his PhD in Neuroscience from Harvard in 2016. His dissertation, Analysis of Voluntary Behavior to Interrogate Neural Function, drew on the devices he built in the Woolf lab.
David co-founded Crimson Scientific, LLC with Lee Barrett in 2017 to build custom behavioral equipment for neuroscience labs: apparatus that recorded high-quality video of mice for manual scoring. The company was profitable every year it operated, and David and Lee closed it in 2023 as his open-field automation company took off. Crimson was the first of three rodent behavioral equipment companies David has started, alongside Blackbox and Virtual Labs.

David joined the Harvard Medical School faculty as Instructor of Neurology (2019–2021) and taught neurobiology of behavior and drug addiction courses at Harvard.

David invented the core technology behind open field behavior-screening company, Blackbox Biotech, as the centerpiece of his dissertation in Harvard’s PhD Program in Neuroscience, then co-founded the company and served as CEO (2022–2026). The company’s patented deeptech platform uses artificial intelligence and machine vision to automate the Open Field Assay, a core experimental approach for behavioral phenotyping of lab mice, improving data quality and reliability for better, faster experiments.
As CEO, David led the company’s growth to $3M in revenue by its third year of business.
David co-founded Cacti Therapeutics, based in Flower Mound, Texas, in 2022. Cacti is developing nociplastigens, a new class of peripherally restricted medicines that target the plasticity mechanisms driving nociplastic pain, including chronic pain tangled with trauma.

2025 Tech Titans Technology Inventor Award. Tech Titans, the technology association for North Texas, gives this award for the creation of breakthrough ideas, processes or products. For David, it recognizes a career spent inventing tools to measure animal behavior.
Today, Virtual Labs is David and a small team of veteran software engineers, AI data scientists, neuroscientists, and business leaders working with us on a fractional basis as we build momentum and funding.
Open Roles
Leads the science behind Virtual Labs: assay design, validation studies, and the scientific rigor behind every measurement we report.
Build and lead our commercial engine — from the first enterprise deals to the team that follows — selling our smart camera hardware and analysis software to pharma, biotech, CROs and academic labs. You’ll also own our partnerships: research collaborations with academic labs that turn early installs into first-in-field publications, strategic alliances with pharma R&D groups and CROs, and channel and distribution partners that take the platform into new markets.
Run the company’s operating rhythm alongside the founder — hiring, finance and vendors, manufacturing and fulfillment logistics, and board and investor preparation — and turn priorities into shipped work across every team.
Pose estimation and behavior classification models for laboratory animals.
Edge AI devices, camera systems, optics integration, and real-time acquisition — instruments designed for machine vision, not for humans.
Our cloud analysis software, data pipelines, and the standardized data schema that ties every device into one dataset.
Assay design, validation studies, and scientific rigor. You’ve run preclinical behavioral studies in mice or rats in orthopedics, neurodegenerative disease or a related field, such as pain and neuropathy, spinal cord, nerve and brain injury, neuromuscular disease, or cognition and social behavior. You know exactly what’s wrong with how those studies are scored today.
Most of our roles will be shaped around exceptional people who are passionate about the mission. People drive growth, not pre-defined positions.
If you want to change how animal science is done, we’re excited to partner with you and hire you. Tell us what you’re great at and why this mission pulls you.
Scientific Advisory Board
Our scientific advisory board brings together leading researchers in behavioral neuroscience, CNS drug development, and computational biology. Advisory positions are currently being established.
Join the Team
We are looking for people who care deeply about both the science and the mission. Tell us what you’re great at and why this mission pulls you.